HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume

HUTCHMED (China) Limited (NASDAQ:HCMGet Rating) saw strong trading volume on Friday . 13,322 shares changed hands during mid-day trading, a decline of 92% from the previous session’s volume of 166,753 shares.The stock last traded at $13.89 and had previously closed at $13.14.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. The Goldman Sachs Group lifted their target price on HUTCHMED from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, August 9th. StockNews.com upgraded HUTCHMED from a “sell” rating to a “hold” rating in a report on Monday, August 1st.

HUTCHMED Stock Up 6.3 %

The stock has a fifty day moving average price of $13.18 and a 200 day moving average price of $14.40.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently modified their holdings of HCM. Quantbot Technologies LP bought a new stake in shares of HUTCHMED during the 1st quarter worth approximately $44,000. US Bancorp DE lifted its stake in shares of HUTCHMED by 270.9% during the 1st quarter. US Bancorp DE now owns 3,687 shares of the company’s stock worth $70,000 after acquiring an additional 2,693 shares during the last quarter. National Pension Service lifted its stake in shares of HUTCHMED by 429.1% during the 2nd quarter. National Pension Service now owns 9,101 shares of the company’s stock worth $115,000 after acquiring an additional 7,381 shares during the last quarter. abrdn plc bought a new stake in shares of HUTCHMED during the 2nd quarter worth approximately $133,000. Finally, Jane Street Group LLC bought a new stake in HUTCHMED during the 2nd quarter valued at $160,000. 27.37% of the stock is owned by institutional investors.

HUTCHMED Company Profile

(Get Rating)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

Featured Articles

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.